Type 2 & other diabetes

The influence of diabetes on temporal trends in lower extremity revascularisation and amputation for peripheral artery disease: A population‐based repeated cross‐sectional analysis

Diabet MedPublished Population-based repeated cross-sectional study

Authors' conclusion

Diabetes prevalence rates strongly influenced rates of revascularisation and amputation related to PAD. A decrease in amputations related to PAD over time was attenuated by rising diabetes prevalence rates.

Study context

Population
Ontario residents aged ≥40 years, 2002–2019; lower extremity revascularisation and amputation related to peripheral artery disease (PAD)
Exposure
2019 vs 2002
Outcome
Annual rates of lower extremity revascularisation (open or endovascular) and amputation (toe, foot or leg) related to PAD; rate ratios relative to 2002, crude, diabetes-adjusted and fully adjusted
Methodological detailsgeneralized estimating equation models
  • Generalized estimating equation models

Main finding

As reported in the abstract

Revascularisation rate
Each group vs 2002Estimate (95% CI)
2019
unadjusted RR 1.10(1.07–1.13)
2019
diabetes-adjusted RR 0.98(0.96–1.01)
2019
fully-adjusted RR 0.94 (95% CI 0.91–0.96)

Observational data: associations, not effects.

Further findings

Outcome20192002Estimate
Amputation rate45.4 /100,000 person-years49.5 /100,000 person-yearsunadjusted RR 0.78 (95% CI 0.75–0.81)
Amputation ratediabetes-adjusted RR 0.62 (95% CI 0.60–0.64)
Amputation ratefully-adjusted RR 0.58 (95% CI 0.56–0.60)

Diabetes prevalence

Diabetes prevalence

Significantly higher diabetes prevalence in 2019 vs 2002

Original publication

The influence of diabetes on temporal trends in lower extremity revascularisation and amputation for peripheral artery disease: A population‐based repeated cross‐sectional analysis. Diabet Med. Published 10 February 2023. doi:10.1111/dme.15056

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.